TD Private Client Wealth’s Apellis Pharmaceuticals APLS Stock Holding History

TD Private Client Wealth’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-56	Closed	-$2.25K	–	1703
2026 Q1	$2.25K	Hold	56	–	–	﹤0.01%	1283
2025 Q4	$1.41K	Sell	56 -38	-40%	-$892	﹤0.01%	1319
2025 Q3	$2.13K	Sell	94 -8	-8%	-$187	﹤0.01%	1241
2025 Q2	$1.77K	Buy	102 +44	+76%	+$814	﹤0.01%	1239
2025 Q1	$1.27K	Hold	58	–	–	﹤0.01%	1262
2024 Q4	$1.85K	Buy	+58	New	+$1.74K	﹤0.01%	1194
2024 Q2	–	Sell	-21	Closed	-$1.23K	–	1219
2024 Q1	$1.23K	Buy	+21	New	+$1.34K	﹤0.01%	1161

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TD Private Client Wealth's APLS Position: Q2 2026 in Review

TD Private Client Wealth sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 56 shares — an estimated $2.25K sold.

TD Private Client Wealth first reported a position in APLS in Q1 2024 and held it in 7 quarters. The position peaked at $2.25K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

TD Private Client Wealth reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
TD Private Client Wealth sold 56 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.25K.
TD Private Client Wealth first reported a position in Apellis Pharmaceuticals in Q1 2024 and held it in 7 quarters.
TD Private Client Wealth's Apellis Pharmaceuticals position peaked at $2.25K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.